S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in
NASDAQ:ALBO

Albireo Pharma News Headlines

$34.85
+0.98 (+2.89 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$32.05
Now: $34.85
$34.88
50-Day Range
$33.87
MA: $37.53
$42.85
52-Week Range
$11.26
Now: $34.85
$49.00
Volume216,145 shs
Average Volume186,215 shs
Market Capitalization$666.12 million
P/E RatioN/A
Dividend YieldN/A
Beta1.62

Headlines

Albireo Pharma (NASDAQ ALBO) News Headlines Today

Source:
SourceHeadline
Zacks Investment Research Upgrades Albireo Pharma (NASDAQ:ALBO) to "Hold"Zacks Investment Research Upgrades Albireo Pharma (NASDAQ:ALBO) to "Hold"
marketbeat.com - February 17 at 3:47 PM
Jan Mattsson Sells 31,470 Shares of Albireo Pharma, Inc. (NASDAQ:ALBO) StockJan Mattsson Sells 31,470 Shares of Albireo Pharma, Inc. (NASDAQ:ALBO) Stock
americanbankingnews.com - March 3 at 9:08 PM
Albireo Pharma, Inc. (NASDAQ:ALBO) to Post Q1 2021 Earnings of ($1.66) Per Share, Piper Sandler ForecastsAlbireo Pharma, Inc. (NASDAQ:ALBO) to Post Q1 2021 Earnings of ($1.66) Per Share, Piper Sandler Forecasts
americanbankingnews.com - March 3 at 8:07 AM
Albireo Pharma (NASDAQ:ALBO) Stock Price Up 6.8% Following Analyst UpgradeAlbireo Pharma (NASDAQ:ALBO) Stock Price Up 6.8% Following Analyst Upgrade
americanbankingnews.com - March 1 at 6:14 PM
Albireo Pharma (NASDAQ:ALBO) Price Target Raised to $81.00Albireo Pharma (NASDAQ:ALBO) Price Target Raised to $81.00
americanbankingnews.com - March 1 at 10:59 AM
Analyzing Eli Lilly and (NYSE:LLY) and Albireo Pharma (NASDAQ:ALBO)Analyzing Eli Lilly and (NYSE:LLY) and Albireo Pharma (NASDAQ:ALBO)
americanbankingnews.com - March 1 at 9:38 AM
Robert W. Baird Reiterates "Buy" Rating for Albireo Pharma (NASDAQ:ALBO)Robert W. Baird Reiterates "Buy" Rating for Albireo Pharma (NASDAQ:ALBO)
americanbankingnews.com - March 1 at 9:05 AM
Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q4 2020 Results - Earnings Call TranscriptAlbireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - February 27 at 9:47 AM
Industry Analysts Just Made A Captivating Upgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) Revenue ForecastsIndustry Analysts Just Made A Captivating Upgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) Revenue Forecasts
finance.yahoo.com - February 27 at 9:47 AM
Albireo Pharma (NASDAQ:ALBO) Issues  Earnings ResultsAlbireo Pharma (NASDAQ:ALBO) Issues Earnings Results
americanbankingnews.com - February 26 at 5:16 PM
Albireo Spotlights Global Patient Communities on Rare Disease DayAlbireo Spotlights Global Patient Communities on Rare Disease Day
finance.yahoo.com - February 26 at 9:05 AM
Albireo Pharma, Inc. (ALBO) Q4 2020 Earnings Call TranscriptAlbireo Pharma, Inc. (ALBO) Q4 2020 Earnings Call Transcript
msn.com - February 26 at 12:40 AM
Albireo Pharma, Inc. 2020 Q4 - Results - Earnings Call PresentationAlbireo Pharma, Inc. 2020 Q4 - Results - Earnings Call Presentation
seekingalpha.com - February 25 at 4:07 PM
Albireo Reports Q4 and Year-End 2020 Financial Results and Business UpdateAlbireo Reports Q4 and Year-End 2020 Financial Results and Business Update
finance.yahoo.com - February 25 at 9:39 AM
Albireo to Participate in Cowen and H.C. Wainwright Global Investor ConferencesAlbireo to Participate in Cowen and H.C. Wainwright Global Investor Conferences
finance.yahoo.com - February 23 at 9:34 AM
Albireo Pharma (ALBO) Scheduled to Post Earnings on ThursdayAlbireo Pharma (ALBO) Scheduled to Post Earnings on Thursday
americanbankingnews.com - February 19 at 10:44 AM
Albireo to Report Q4 and Year-End 2020 Financial Results on February 25Albireo to Report Q4 and Year-End 2020 Financial Results on February 25
finance.yahoo.com - February 18 at 8:46 AM
Did Albireo Pharmas (NASDAQ:ALBO) Share Price Deserve to Gain 81%?Did Albireo Pharma's (NASDAQ:ALBO) Share Price Deserve to Gain 81%?
finance.yahoo.com - February 5 at 10:21 AM
Albireo Pharma: De-Risked Small-Cap Biotech Ready For CommercializationAlbireo Pharma: De-Risked Small-Cap Biotech Ready For Commercialization
seekingalpha.com - January 27 at 7:12 AM
Albireo to Participate in H.C. Wainwright BioConnect and LifeSci Advisors Investor ConferencesAlbireo to Participate in H.C. Wainwright BioConnect and LifeSci Advisors Investor Conferences
finance.yahoo.com - January 5 at 8:58 AM
Is ALBO A Good Stock To Buy Now?Is ALBO A Good Stock To Buy Now?
finance.yahoo.com - December 19 at 6:54 PM
Albireo Initiates Global Phase 3 Clinical Trial of Odevixibat in Alagille SyndromeAlbireo Initiates Global Phase 3 Clinical Trial of Odevixibat in Alagille Syndrome
finance.yahoo.com - December 17 at 9:38 AM
Albireo Submits for U.S. FDA and EMA Product Approval of Once-Daily Odevixibat for PFICAlbireo Submits for U.S. FDA and EMA Product Approval of Once-Daily Odevixibat for PFIC
finance.yahoo.com - December 8 at 4:39 PM
The Petri Dish: Wyss Institutes VC partnership and a health tech firm eyes M&AThe Petri Dish: Wyss Institute's VC partnership and a health tech firm eyes M&A
bizjournals.com - November 19 at 8:09 AM
Albireo Pharmas odevixibat shows durable response in a rare pediatric liver diseaseAlbireo Pharma's odevixibat shows durable response in a rare pediatric liver disease
seekingalpha.com - November 13 at 9:31 PM
Albireo to Participate in Jefferies and Piper Sandler Virtual Investor ConferencesAlbireo to Participate in Jefferies and Piper Sandler Virtual Investor Conferences
finance.yahoo.com - November 12 at 1:03 PM
The Albireo Pharma, Inc. (NASDAQ:ALBO) Third-Quarter Results Are Out And Analysts Have Published New ForecastsThe Albireo Pharma, Inc. (NASDAQ:ALBO) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
nasdaq.com - November 7 at 12:42 PM
Albireo Pharma, Inc. (NASDAQ:ALBO) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?Albireo Pharma, Inc. (NASDAQ:ALBO) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
finance.yahoo.com - November 7 at 7:39 AM
Albireo Pharma EPS misses by $0.45, beats on revenueAlbireo Pharma EPS misses by $0.45, beats on revenue
seekingalpha.com - November 5 at 10:00 AM
Albireo Reports Q3 2020 Financial Results and Provides Business UpdateAlbireo Reports Q3 2020 Financial Results and Provides Business Update
finance.yahoo.com - November 5 at 10:00 AM
Albireo’s Odevixibat PFIC Phase 3 Results Accepted for AASLD Late-BreakersAlbireo’s Odevixibat PFIC Phase 3 Results Accepted for AASLD Late-Breakers
finance.yahoo.com - November 2 at 12:31 PM
Albireo Announces Presentations at NASPGHAN 2020 Annual MeetingAlbireo Announces Presentations at NASPGHAN 2020 Annual Meeting
finance.yahoo.com - October 23 at 9:52 AM
Insider Buys Albireo Pharma's SharesInsider Buys Albireo Pharma's Shares
finance.yahoo.com - September 15 at 7:31 PM
Insider Buys Albireo Pharmas SharesInsider Buys Albireo Pharma's Shares
benzinga.com - September 15 at 2:30 PM
Albireos Positive Data, And Other News: The Good, Bad And Ugly Of BiopharmaAlbireo's Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
seekingalpha.com - September 11 at 7:49 AM
Albireo Prices Public Offering of 4,000,000 Shares of Common StockAlbireo Prices Public Offering of 4,000,000 Shares of Common Stock
finance.yahoo.com - September 10 at 5:32 AM
Albireo Announces Proposed Public Offering of 3,000,000 Shares of Common StockAlbireo Announces Proposed Public Offering of 3,000,000 Shares of Common Stock
finance.yahoo.com - September 8 at 6:50 PM
Mid-Morning Market Update: Markets Open Lower; Grifols To Buy Geriatric Pharma Startup AlkahestMid-Morning Market Update: Markets Open Lower; Grifols To Buy Geriatric Pharma Startup Alkahest
benzinga.com - September 8 at 1:50 PM
Albireo up 10% ahead of late-stage odevixibat data readoutAlbireo up 10% ahead of late-stage odevixibat data readout
seekingalpha.com - September 8 at 8:49 AM
Albireo Phase 3 Trial Meets Both Primary Endpoints for Odevixibat in PFICAlbireo Phase 3 Trial Meets Both Primary Endpoints for Odevixibat in PFIC
finance.yahoo.com - September 8 at 8:49 AM
Is the Options Market Predicting a Spike in Albireo Pharma (ALBO) Stock?Is the Options Market Predicting a Spike in Albireo Pharma (ALBO) Stock?
finance.yahoo.com - September 3 at 10:29 AM
How Much Of Albireo Pharma, Inc. (NASDAQ:ALBO) Do Institutions Own?How Much Of Albireo Pharma, Inc. (NASDAQ:ALBO) Do Institutions Own?
finance.yahoo.com - August 27 at 8:37 AM
Albireo (ALBO) Looks Good: Stock Adds 5.1% in SessionAlbireo (ALBO) Looks Good: Stock Adds 5.1% in Session
finance.yahoo.com - August 21 at 2:22 PM
Albireo Down on Unimpressive Data From Mid-Stage NASH StudyAlbireo Down on Unimpressive Data From Mid-Stage NASH Study
finance.yahoo.com - August 19 at 3:16 PM
Albireo under pressure on elobixibat strikeout in NASHAlbireo under pressure on elobixibat strikeout in NASH
seekingalpha.com - August 18 at 5:56 PM
Albireo Reports Topline Results from Phase 2 Trial of Elobixibat in NAFLD/NASHAlbireo Reports Topline Results from Phase 2 Trial of Elobixibat in NAFLD/NASH
finance.yahoo.com - August 18 at 5:56 PM
Albireo Corporate Updates, And Other News: The Good, Bad And Ugly Of BiopharmaAlbireo Corporate Updates, And Other News: The Good, Bad And Ugly Of Biopharma
seekingalpha.com - August 10 at 11:43 PM
Albireo Pharma, Inc.s (ALBO) CEO Ron Cooper on Q2 2020 Results - Earnings Call TranscriptAlbireo Pharma, Inc.'s (ALBO) CEO Ron Cooper on Q2 2020 Results - Earnings Call Transcript
seekingalpha.com - August 8 at 5:39 PM
Albireo Pharma, Inc. (ALBO) Q2 2020 Earnings Call TranscriptAlbireo Pharma, Inc. (ALBO) Q2 2020 Earnings Call Transcript
fool.com - August 7 at 6:48 PM
Albireo Pharma EPS beats by $0.28, beats on revenueAlbireo Pharma EPS beats by $0.28, beats on revenue
seekingalpha.com - August 6 at 12:35 PM
Albireo Reports Q2 2020 Financial Results and Provides Business UpdateAlbireo Reports Q2 2020 Financial Results and Provides Business Update
finance.yahoo.com - August 6 at 7:35 AM
This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.